Encephalitis Treatments

Find Encephalitis Treatments

Brand Name

Foscavir

Generic Name

Foscarnet

View Brand Information

FDA approval date: July 09, 2012

Classification: Pyrophosphate Analog DNA Polymerase Inhibitor

Form: Injection

What is Foscavir (Foscarnet)?

CMV Retinitis FOSCAVIR is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome . Combination therapy with FOSCAVIR and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS ; CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. Mucocutaneous Acyclovir Resistant HSV Infections FOSCAVIR is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS ; CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Study of CMV Specific Immune Reconstitution in Patients With Clinical Significant CMV Infection After Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Enrollment Status: Recruiting

Publish Date: July 07, 2026

Intervention Type: Drug

Summary: Cytomegalovirus (CMV) reactivation is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI) plays a key role in viral control. This prospective, exploratory study will enroll 40 adult CMV-seropositive patients who experience their first CMV reactivation after allo-HSCT. CMV-spe...

An Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Maribavir in Chinese Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Cidofovir or Foscarnet

Enrollment Status: Recruiting

Publish Date: March 02, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The main aim of this study is to learn how safe maribavir is in Chinese adults who have undergone hematopoietic stem cell or organ transplantation and have a cytomegalovirus (CMV) infection and how well they tolerate treatment with maribavir. Other aims are to see how effective maribavir is in treating CMV infection and getting rid of the symptoms, the recurrence rate of CMV infection after treatm...

Pharmacokinetics of Drugs Administered to Children Per Standard of Care

Enrollment Status: Recruiting

Publish Date: January 07, 2026

Intervention Type: Drug

Summary: This is a prospective study of children \<21 years of age with the goal of characterizing the PK of drugs administered per standard of care as prescribed by the treating caregiver.

View All Clinical Trials

Related Latest Advances

Encephalopathy Post CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Beyond ICANS.

Journal: Journal of investigative medicine high impact case reports

Published: August 10, 2026

HHV-7 encephalitis following allogeneic hematopoietic stem cell transplantation: A case report and literature review.

Journal: Cell transplantation

Published: August 05, 2026

Varicella zoster virus infection.

Journal: Nature reviews. Disease primers

Published: August 05, 2026

View All Latest Advances